← Eichor
Study identifier: NCT05661461 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

Condition: Tumor, Solid · Tumor · Advanced Solid Tumor  ·  Sponsor: Aadi Bioscience, Inc.

PhasePhase 1
Planned participants28
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.

This description comes directly from the study's public registry record.

Talk to the study team

Aadi Medical Information  ·  1-888-246-2234  ·  MedInfo@aadibio.com

Always discuss trial participation with your own doctor first.

Locations (2)

South Texas Accelerated Research Therapeutics, LLCSan Antonio, Texas, United StatesRecruiting
START Mountain RegionWest Valley City, Utah, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05661461